Show simple item record

AuthorJahrsdörfer, Bernddc.contributor.author
AuthorFabricius, Doritdc.contributor.author
AuthorScholz, Judithdc.contributor.author
AuthorLudwig, Carolindc.contributor.author
AuthorGrempels, Alinedc.contributor.author
AuthorLotfi, Ramindc.contributor.author
AuthorKörper, Sixtendc.contributor.author
AuthorAdler, Guidodc.contributor.author
AuthorSchrezenmeier, Hubertdc.contributor.author
Date of accession2022-02-07T12:37:02Zdc.date.accessioned
Available in OPARU since2022-02-07T12:37:02Zdc.date.available
Date of first publication2021-09-29dc.date.issued
AbstractElderly residents of long-term care facilities (LTCFs) have long been underrepresented in studies on vaccine efficacy, particularly in light of currently emerging variants of concern (VOCs). In this prospective observational cohort study, we analyzed serological immune responses in 190 individuals before, 3 weeks after 1st and 3 weeks after 2nd vaccination with BNT162b2. Unvaccinated COVID-19-convalescent subjects served as reference. End points comprised serum anti-spike IgG and IgA titers as well as neutralization capacities against unmutated and mutated SARS-CoV-2 receptor binding domains including B.1.1.7, B.1.351 and P.1. We found that antibody titers and neutralization capacities up to 3 weeks after 2nd vaccination with BNT162b2 were significantly higher in COVID-19-convalescent as compared to COVID-19-naive vaccinees. Moreover, prevaccination anti-NCP IgG titers, but not age or gender, had a high impact on the strength and kinetics of post-vaccination neutralization capacity development. Most importantly, BNT162b2-induced neutralization capacity was cross-reactive with VOCs. In contrast to unvaccinated convalescents, vaccinated convalescent individuals of all ages acquired strong neutralizing capacities against current VOCs. The present study suggests that COVID-19-convalescent individuals with a broad age range between 18 and 98 years benefit from BNT162b2 vaccination by developing strong and broad neutralizing immune responses against SARS-CoV-2 including current VOCs.dc.description.abstract
Languageendc.language.iso
PublisherUniversität Ulmdc.publisher
LicenseCC BY 4.0 Internationaldc.rights
Link to license texthttps://creativecommons.org/licenses/by/4.0/dc.rights.uri
KeywordmRNA vaccinedc.subject
KeywordComirnatydc.subject
KeywordB.1.1.7dc.subject
KeywordB.1.351dc.subject
KeywordP.1dc.subject
KeywordBNT162b2dc.subject
Dewey Decimal GroupDDC 610 / Medicine & healthdc.subject.ddc
MeSHCOVID-19 vaccinesdc.subject.mesh
MeSHRNA, Messenger; Therapeutic usedc.subject.mesh
MeSHNeutralization testsdc.subject.mesh
TitleBNT162b2 vaccination elicits strong serological immune responses against SARS-CoV-2 including variants of concern in elderly convalescentsdc.title
Resource typeWissenschaftlicher Artikeldc.type
VersionpublishedVersiondc.description.version
DOIhttp://dx.doi.org/10.18725/OPARU-41417dc.identifier.doi
URNhttp://nbn-resolving.de/urn:nbn:de:bsz:289-oparu-41493-0dc.identifier.urn
GNDCOVID-19dc.subject.gnd
GNDImpfungdc.subject.gnd
GNDMessenger-RNSdc.subject.gnd
FacultyMedizinische Fakultätuulm.affiliationGeneral
InstitutionUKU. Institut für Transfusionsmedizinuulm.affiliationSpecific
InstitutionInstitut für Klinische Transfusionsmedizin und Immungenetik Ulm gGmbH (IKT)uulm.affiliationSpecific
InstitutionUKU. Klinik für Kinder- und Jugendmedizinuulm.affiliationSpecific
Peer reviewjauulm.peerReview
DCMI TypeTextuulm.typeDCMI
CategoryPublikationenuulm.category
DOI of original publication10.3389/fimmu.2021.743422dc.relation1.doi
Source - Title of sourceFrontiers in Immunologysource.title
Source - Place of publicationFrontiers Mediasource.publisher
Source - Volume12source.volume
Source - Year2021source.year
Source - Article number743422source.articleNumber
Source - eISSN1664-3224source.identifier.eissn
EU project uulmSUPPORT-E / SUPporting high quality evaluation of COVID-19 convalescent Plasma thrOughoutT Europe / EC / H2020 / 101015756uulm.projectEU
Open Accessgold, Green Publisheduulm.OA
WoS000717171600001uulm.identifier.wos
Bibliographyuulmuulm.bibliographie
Is Supplemented Byhttps://www.frontiersin.org/articles/10.3389/fimmu.2021.743422/full#supplementary-materialdc.relation.isSupplementedBy
xmlui.metadata.uulm.OAfundingOpen-Access-Förderung durch die Medizinische Fakultät der Universität Ulmuulm.OAfunding


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record